Terumo BCT Inc - Company Profile
Powered by 
All the data and insights you need on Terumo BCT Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Terumo BCT Inc Strategy Report
- Understand Terumo BCT Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Terumo BCT Inc (Terumo BCT), a subsidiary of Terumo Corp, provides blood components, therapeutic apheresis, and cellular technologies. The company’s key products include an automated blood collection system, information system, data collection system, apheresis system, cell processor, cell separation system, pathogen reduction technology system, whole blood processing system, cell expansion system, orbisac system, sterile tubing welder, tube sealing device, blood bag system, and ancillary products for blood centers. Its technologies and systems are used in immunotherapy, gene therapy, and cell therapy. Terumo BCT serves blood centers, cell collection, and processing organizations, hospitals, therapeutic apheresis clinics, researchers, and private medical practices. The company has manufacturing facilities in India, Japan, Belgium, Northern Ireland, Vietnam, and the US; and sells products the world over through subsidiaries and offices. Terumo BCT is headquartered in Lakewood, Colorado, the US.
Headquarters
United States of America
Address
10811 West Collins Avenue, Lakewood, Colorado, 80215
Website
www.terumobct.com
Telephone
1 303 2314357
No of Employees
30,000
Industry
Medical Equipment
Terumo BCT Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Trima Accel Collection System | - |
| Spectra Optia Apheresis System | Trima Accel |
| COBE Spectra Apheresis System | TACSI |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2022 | Contracts/Agreements | In July, the company entered into a partnership agreement with Eliaz Therapeutics for the development of therapeutic treatment for acute kidney injury (AKI). |
| 2022 | Contracts/Agreements | In June, the company entered into a collaboration agreement with Gencure for the development of gene therapy manufacturing solutions. |
| 2021 | Contracts/Agreements | In November, the company and Immunicom entered into an agreement to launch breakthrough cancer immunotherapy treatment in Europe. |
Competitor Comparison
| Key Parameters | Terumo BCT Inc | GE HealthCare Technologies Inc | Sartorius AG | Haemonetics Corp | Sotera Health Co |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | Germany | United States of America | United States of America |
| City | Lakewood | Chicago | Goettingen | Boston | Broadview Heights |
| State/Province | Colorado | Illinois | Hessen | Massachusetts | Ohio |
| No. of Employees | 30,000 | 51,000 | 14,614 | 3,034 | 3,000 |
| Entity Type | Private | Public | Public | Public | Public |
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Antoinette Gawin | President; Chief Executive Officer | Senior Management | - | - |
| Rusty Spinney | Chief Financial Officer; Executive Vice President | Senior Management | - | - |
| Janet Johnson | Vice President - Global Regulatory Affairs and Labeling | Senior Management | - | - |
| Varaprasad Manne | Vice President - Global Quality | Senior Management | - | - |
| Cindy Ng | Senior Vice President - Global Commercial | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer